romosozumab sold brand name evenity medication used treat found decrease risk fractures common side effects include headache joint pain injection site reactions including may increase risk heart attacks strokes deaths cardiovascular humanized monoclonal antibody targets research shows drug increases bone formation decreases bone resorption postmenopausal women low bone density romosozumab approved medical use japan united states european union us food drug administration fda considers firstinclass romosozumab used osteoporosis decrease risk two trials found reduced rate vertebral fracture one lower risk vertebral fracture one year benefit maintained second year taking denosumab one year romosozumab followed one year alendronate vertebral fracture reduction compared two years common side effects include headache joint pain injection site reactions including one trial patients romosozumab group serious cardiovascular events compared alendronate group vs though found trial romosozumab vs currently drug contains boxed warning labeling stating may increase risk heart attack stroke cardiovascular death used patients heart attack stroke within previous romosozumab approved medical use japan january united states april european union december originally discovered acquired celltech nowwhen owned celltech entered partnership amgen products uks nice provisionally decided recommend romosozumab use england httpsenwikipediaorgwikiromosozumab